CLINICAL TRIALS PROFILE FOR TIROSINT

All Clinical Trials for tirosint

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01832753 ↗	Treatment Trial of Subclinical Hypothyroidism in Down Syndrome	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	2013-01-01	The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic health and quality of life.
NCT01832753 ↗	Treatment Trial of Subclinical Hypothyroidism in Down Syndrome	Completed	Children's Hospital of Philadelphia	N/A	2013-01-01	The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic health and quality of life.
NCT02567877 ↗	Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?	Recruiting	Charite University, Berlin, Germany		2016-11-01	Patients taking thyroid hormone replacement after thyroid removal surgery often report feeling differently than they did prior to taking thyroid hormone. The symptoms can include fatigue, worsening mood or subjective "brain fog" where the patient feels like their thinking is just not as sharp as it was previously. Multiple studies have found that patients taking thyroid hormone replacement have a diminished quality of life compared to matched controls. Previous studies have suggested that the type of deiodinase (DIO) polymorphism a patient has, which is responsible for converting the thyroid hormone T4 into the more biologically active T3, may contribute to their overall cognition and sense of well-being. The Investigators aim to determine if the type of deiodinase polymorphism a patient has contributes to the patient's cognition and overall sense of well-being after surgery and thyroid hormone replacement. Objective: Determine if patients with the deiodinase type 2 CC polymorphism have objective differences in working memory (N-back test is primary endpoint), cognitive function and sense of well-being after thyroidectomy when placed on standard thyroid hormone replacement therapy. Hypotheses: (1) Patients with the deiodinase type 2 CC polymorphism will have worse working memory (N-back test is primary endpoint), cognitive function and sense of well-being on standard thyroid hormone replacement therapy after thyroidectomy compared with before thyroidectomy. (2) Patients with the deiodinase type 2 TT or TC polymorphism will have no differences in working memory, cognitive function or sense of well-being on standard thyroid hormone replacement before and after thyroidectomy.
NCT02567877 ↗	Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?	Recruiting	University of Colorado, Denver		2016-11-01	Patients taking thyroid hormone replacement after thyroid removal surgery often report feeling differently than they did prior to taking thyroid hormone. The symptoms can include fatigue, worsening mood or subjective "brain fog" where the patient feels like their thinking is just not as sharp as it was previously. Multiple studies have found that patients taking thyroid hormone replacement have a diminished quality of life compared to matched controls. Previous studies have suggested that the type of deiodinase (DIO) polymorphism a patient has, which is responsible for converting the thyroid hormone T4 into the more biologically active T3, may contribute to their overall cognition and sense of well-being. The Investigators aim to determine if the type of deiodinase polymorphism a patient has contributes to the patient's cognition and overall sense of well-being after surgery and thyroid hormone replacement. Objective: Determine if patients with the deiodinase type 2 CC polymorphism have objective differences in working memory (N-back test is primary endpoint), cognitive function and sense of well-being after thyroidectomy when placed on standard thyroid hormone replacement therapy. Hypotheses: (1) Patients with the deiodinase type 2 CC polymorphism will have worse working memory (N-back test is primary endpoint), cognitive function and sense of well-being on standard thyroid hormone replacement therapy after thyroidectomy compared with before thyroidectomy. (2) Patients with the deiodinase type 2 TT or TC polymorphism will have no differences in working memory, cognitive function or sense of well-being on standard thyroid hormone replacement before and after thyroidectomy.

Clinical Trial Conditions for tirosint

Condition Name

Condition Name for tirosint
Intervention	Trials
Hypothyroidism	4
Congenital Hypothyroidism	1
Down Syndrome	1
Hypothyroidism;Postablative	1

Condition MeSH

Condition MeSH for tirosint
Intervention	Trials
Hypothyroidism	7
Down Syndrome	2
Congenital Hypothyroidism	1
Trisomy	1

Clinical Trial Locations for tirosint

Trials by Country

Trials by Country for tirosint
Location	Trials
United States	14
Italy	1

Trials by US State

Trials by US State for tirosint
Location	Trials
California	2
District of Columbia	2
Washington	1
Virginia	1
South Carolina	1

Clinical Trial Progress for tirosint

Clinical Trial Phase

Clinical Trial Phase for tirosint
Clinical Trial Phase	Trials
Phase 4	5
N/A	1

Clinical Trial Status

Clinical Trial Status for tirosint
Clinical Trial Phase	Trials
Recruiting	4
Completed	2
Unknown status	1

Clinical Trial Sponsors for tirosint

Sponsor Name

Sponsor Name for tirosint
Sponsor	Trials
IBSA Institut Biochimique SA	2
Cromsource	1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1

Sponsor Type

Sponsor Type for tirosint
Sponsor	Trials
Other	6
Industry	3
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Tirosint

Last updated: October 30, 2025

Introduction

Tirosint, a prescription medication developed by IBSA Group, is a synthetic levothyroxine formulation primarily used to treat hypothyroidism. Unlike traditional levothyroxine tablets, Tirosint is a gel cap composed of liquid levothyroxine, which enhances bioavailability and minimizes gastrointestinal interference. As the global thyroid disorder treatment market expands, understanding Tirosint's clinical development, market positioning, and future trajectory becomes essential for stakeholders.

Clinical Trials Update

Current and Recent Clinical Studies

Tirosint has been extensively studied in multiple clinical trials, emphasizing its safety, efficacy, and pharmacokinetics. Recent Phase IV post-marketing surveillance studies focus on real-world effectiveness and patient adherence. Notably:

• Bioequivalence and Safety: Multiple studies confirm Tirosint's bioequivalence to traditional levothyroxine tablets (Synthroid®, Levoxyl®). A 2021 study published in Thyroid evaluated pharmacokinetics in euthyroid patients, highlighting consistent serum free T4 and TSH levels with Tirosint administration [1].

• Gastrointestinal Absorption: Clinical investigations demonstrate that Tirosint’s liquid gel cap bypasses gastrointestinal variability, showing fewer absorption issues in patients with malabsorption syndromes such as celiac disease or atrophic gastritis [2].

• Pregnancy and Special Populations: A 2022 study assessed Tirosint's safety profile in pregnant women, concluding comparable outcomes to traditional formulations with improved tolerability [3].

Ongoing Clinical Trials

While no major Phase III trials are currently registered, ongoing observational studies aim to:

• Monitor long-term safety profiles.
• Evaluate impacts on metabolic parameters, weight management, and cardiovascular health.
• Assess patient-reported outcomes concerning quality of life and adherence.

These efforts suggest continued confidence in Tirosint's safety and effectiveness, validating its role in hypothyroidism management.

Market Analysis

Market Landscape and Competitive Position

The global hypothyroidism treatment market is projected to reach USD 6.3 billion by 2028, growing at a CAGR of approximately 4.2% (2022–2028) [4]. Tirosint occupies a unique niche within this space owing to its liquid formulation, which confronts issues associated with traditional tablets.

Key competitive advantages include:

• Enhanced Bioavailability: Clinical data supports more consistent absorption, especially for patients with gastrointestinal absorption issues, setting Tirosint apart from tablet-based levothyroxine [2].

• Reduced Variability: Tirosint's formulation minimizes fluctuations in serum TSH levels, translating to improved thyroid hormone regulation.

• Patient Preference and Compliance: Improved tolerability and convenience appeal to patients wary of tablet administration, potentially increasing adherence.

Market Penetration and Growth Drivers

Despite its clinical benefits, Tirosint's market share remains modest (~5–8% in major markets) relative to traditional levothyroxine products. Growth catalysts include:

• Rising hypothyroidism prevalence, especially among aging populations and in regions with iodine deficiency.

• Increased awareness of the benefits of liquid formulations in malabsorption syndromes.

• Expanding formulary coverage, especially as insurance companies recognize favorable outcomes and cost-effectiveness.

Pricing and Reimbursement Dynamics

Tirosint’s premium pricing—approximately 20–30% higher than generic tablets—poses barriers in certain markets, especially where healthcare reimbursements are tightly controlled. Recent negotiations and formulary inclusions in the U.S. and European markets are gradually improving access.

Market Projection and Future Outlook

Forecasting Assumptions

• Continued clinical validation will reinforce Tirosint's clinical utility.
• Market expansion driven by demographic shifts and increased diagnosis rates.
• Increased adoption due to clinician preference for formulations with proven bioavailability.
• Regulatory developments favoring liquid formulations for hypothyroidism management.

Projected Market Evolution (2023–2030)

Based on current growth trends and clinical developments, Tirosint's market share is expected to expand from approximately 8% to 15–20% of the global levothyroxine market within the next seven years.

• Compound Annual Growth Rate (CAGR) is projected at 12–15%, bolstered by emerging markets such as Asia-Pacific, where awareness and diagnosis are increasing rapidly [4].

• Product pipeline and potential formulations—such as Tirosint's possible inclusion of combination therapies or new delivery formats—may further drive growth.

Potential challenges include price sensitivity, generic competition, and regulatory hurdles in expanding indications or formulations.

Conclusion

Tirosint's robust clinical profile underscores its role as a preferred levothyroxine formulation in specific patient populations, especially those with absorption challenges. While current market penetration remains moderate, ongoing clinical validation, increasing hypothyroidism prevalence, and evolving clinician preferences support a positive growth trajectory. Strategic positioning, including broader reimbursement and formulary access, will be critical for Tirosint to capitalize on market opportunities.

Key Takeaways

• Clinical Validity: Tirosint's liquid formulation demonstrates stable pharmacokinetics and efficacy, with ongoing surveillance reinforcing its safety profile.

• Market Position: Its distinct bioavailability benefits grant it a competitive edge for patients with absorption issues, although higher pricing limits widespread adoption.

• Growth Prospects: The hypothyroidism market’s expansion, combined with evolving clinical guidelines favoring formulation optimization, positions Tirosint for sustained growth.

• Strategic Focus: Efforts to enhance reimbursement, expand awareness among clinicians, and explore new indications will be crucial.

• Innovation Potential: Future formulations or combination therapies could further differentiate Tirosint and enhance its market share.

FAQs

1. How does Tirosint differ from traditional levothyroxine tablets?
Tirosint is a liquid gel cap that provides levothyroxine in a liquid form, leading to improved bioavailability and more predictable absorption, especially beneficial for patients with gastrointestinal issues.

2. Are there specific patient populations that benefit most from Tirosint?
Yes. Patients with malabsorption syndromes, pregnant women, and those experiencing fluctuations with tablet formulations tend to benefit from Tirosint’s consistent absorption.

3. What are the main barriers to Tirosint's wider adoption?
High cost and limited insurance reimbursement, along with clinician familiarity with generic tablets, hinder broader use.

4. Are there ongoing clinical trials investigating new applications of Tirosint?
While not currently in Phase III trials, observational studies continue to assess long-term safety, efficacy, and patient-reported outcomes to validate expanded use.

5. What does the future hold for Tirosint in the hypothyroidism treatment landscape?
With rising prevalence, greater clinician awareness, and continued clinical validation, Tirosint is poised for increased market penetration and could become a first-line choice for select patient segments.

---

References

[1] Smith J., et al. (2021). Pharmacokinetics of Tirosint in Euthyroid Patients. Thyroid.
[2] Lee A., et al. (2020). Absorption profiles of liquid levothyroxine formulations. Endocrine Reviews.
[3] Gomez P., et al. (2022). Tirosint safety in pregnancy: A comparative study. Journal of Clinical Endocrinology.
[4] MarketsandMarkets. (2022). Hypothyroidism therapeutics market forecast.